Improving our understanding of viruses to help develop new medicines

Based on research at University College London, Arrow Therapeutics has developed an array of potential candidates for novel anti-viral drugs. Basic Research by Professor Ian Charles into molecular pathogenicity led to the creation of a novel technology termed Transposon-mediated Differential Hybridisation (TMDH), which allows researchers to analyse the genes of a target organism.

Arrow therapeutics was purchased by Astra Zeneca in 2007 for around $150m in cash, generating large financial returns for the researchers and the university. The products being developed by the company work to combat important pathogens such as Hepatitis C and Respiratory Syncytial Virus (RSV): they could therefore have enormous impacts on healthcare, and potentially save many lives.

Related case studies

Reducing blood transfusions to lower patient risk, reduce costs and save lives

More than half a million people in the UK receive a blood transfusion each year and demand is increasing. Our ageing population, and a stringent donor selection process, mean the supply of blood is limited. 40% fewer new donors came forward last year compared with a decade ago. Recognising these challenges, researchers at the University of Edinburgh have shown the benefits of reducing the use of blood transfusions in intensive care and surgery.

Read more >